Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel and Temozolomide in Newly Diagnosed High Grade Glioma
NCT00660283Phase 2Unknown
- Sponsor
- Kentuckiana Cancer Institute
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, temozolomide in glioma, sponsored by Kentuckiana Cancer Institute. Status: unknown.
02
Drugs
carmustinetemozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00660283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660283.